Drug Trial Radar · NCT05337345
A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Feb 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
104
Actual
Start
May 2, 2022
Primary completion
Dec 15, 2022
Study completion Dec 15, 2022
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Apr 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the drug levels of cendakimab delivered subcutaneously in healthy participants.
Conditions
- Healthy Volunteers
Interventions
CendakimabDrug
Specified Dose on Specified Days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed concentration (Cmax)Time frame: Up to Day 105
- Area under the concentration-time curve (AUC) from time zero to time of last quantifiable concentration (AUC(0-T))Time frame: Up to Day 105
- AUC from time zero extrapolated to infinite time (AUC(INF))Time frame: Up to Day 105
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Anaheim Clinical Trials Llc
Anaheim, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.